1. Introduction {#s0005}
===============

Depression and anxiety are public health challenges worldwide, contributing an enormous amount of human misery and lost health. Depression and anxiety commonly affect patients with chronic conditions, such as obstructive sleep apnoea (OSA) and cardiovascular (CV) disease, and they adversely impact on prognosis, quality of life and treatment adherence [@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025]. The relationship between abnormal mood and OSA is complex and bidirectional, with various potential pathophysiological mechanisms including sleep fragmentation, hypoxia, oxidative stress, inflammation and neurotransmitter imbalance [@bb0030], [@bb0035]. While continuous positive airway pressure (CPAP), the most widely used treatment for OSA, improves subjective symptoms such as daytime sleepiness, the effects specifically on depression and anxiety are uncertain. Two recent systematic reviews of randomised trials on the effect of CPAP on depression and anxiety reported conflicting conclusions [@bb0040], [@bb0045]. Existing findings are variable across studies due, in part, to different study designs, small patient numbers, short periods of follow-up, and from an emphasis on depression over anxiety patterns of abnormal mood [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120].

The international multicenter Sleep Apnea Cardiovascular Endpoints (SAVE) study assessed the effectiveness of CPAP treatment for the prevention of serious CV events in 2717 patients with co-existing OSA and coronary and/or cerebrovascular CV disease. A secondary aim was to determine whether CPAP reduced depression and anxiety symptoms, and statistically significant reductions were apparent at the end-of-study visit after several years of treatment in addition to usual care, compared to usual care alone [@bb0125]. Herein, we provide in-depth analyses of the temporal effects of CPAP on depression and anxiety among SAVE participants, with the aim of defining subgroups of patients who may derive the greatest benefit from treatment and the interaction of CPAP treatment related effects on mood with improved sleepiness. We also sought to quantify the relevance of these findings in the context of a systematic review of the randomised evidence to provide a robust estimate of the effects of CPAP on depression and anxiety symptoms in patients with OSA. We hypothesised that CPAP treatment would lead to reductions in both depression and anxiety symptoms overtime in OSA patients independent of improvements in daytime sleepiness.

2. Methods {#s0010}
==========

2.1. Clinical trial design and participants {#s0015}
-------------------------------------------

We conducted a secondary analysis of the SAVE study which was an international, multi-center, randomised, open, blinded-outcome assessed, controlled trial of the effectiveness of CPAP for OSA for secondary prevention of CV disease, the details of which are outlined elsewhere [@bb0125]. In brief, patients with a history of CV disease and moderate to severe OSA (≥ 4% oxygen desaturation index, ≥ 12 events/h \[ApneaLink, ResMed\]) during an overnight recording were recruited from 89 clinical centres in seven countries between December 2008 and November 2013. Patients were excluded if they had severe oxygen desaturation (\< 80% SpO~2~ for \> 10% of the monitoring time), severe daytime sleepiness (Epworth Sleepiness Scale \[ESS\] score \> 15), or predominant central apnoea. Eligible participants were also required to have used an average of at least 3 h per night of sham-CPAP during a one week run-in period. The study was approved by all relevant ethics committees, and written informed consent was obtained from each participant or their appropriate surrogate. The study is registered at [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0005} ([NCT00738179](NCT00738179){#ir0010}).

2.2. Randomisation and interventions {#s0020}
------------------------------------

Eligible patients were randomised centrally to receive either CPAP therapy plus usual care (CPAP group) or usual care alone (usual-care group). Randomisation was stratified by site, type of CV disease (cardiac, cerebrovascular, or both), and severity of daytime sleepiness (ESS score \< 11 vs. ≥ 11). CPAP group patients were provided with an automated CPAP machine (REMstar Auto, M or PR series, Philips Respironics) that was initially set in automatic mode for one week and thereafter fixed to the 90th percentile of pressure that was calculated by the automated positive airway pressure device from the recorded data. The core sleep laboratory monitored CPAP adherence and all patients had guideline management of CV risk factors and were provided advice on beneficial sleep habits and lifestyle changes to minimise OSA symptoms.

2.3. Procedures and outcomes {#s0025}
----------------------------

Information on demographic and clinical characteristics, medical history, medications, and health behaviours was recorded at the time of enrolment. Anxiety and depression symptoms were assessed at baseline, and at 6-, 24-, 48-, 72-, and 84-month visits (or end of study, whichever came first), using the Hospital Anxiety and Depression Scale (HADS). The HADS is a widely used screening tool for abnormal mood, with subscales HADS-D and HADS-A each containing 7 items relevant to depression and anxiety symptoms, respectively. HADS subscale scores range from 0 to 21 and can be used to categorise mood as: 0--7 'non-case'; 8--10 'possible case'; and 11--21 for 'definite case' of depression or anxiety [@bb0130], [@bb0135]. For the main analyses, we defined depression and anxiety 'non-caseness' as having a HADS score of 0--7; and 'caseness' as having a HADS score of 8--21, as a cut-off score of 8 was found to be optimal for best sensitivity and specificity [@bb0130].

2.4. Statistical analysis {#s0030}
-------------------------

Baseline patient characteristics were summarised as mean (SD) for continuous variables, and as number (%) for categorical variables, with comparisons between groups made using Wilcoxon or chi-squared tests. Unadjusted logistic regression was conducted to evaluate the relationship between CPAP and depression and anxiety caseness at the end of follow-up, as defined by scores ≥ 8 on each of the HADS-D and HADS-A subscales. Sensitivity analyses were performed with the higher cut-point of ≥ 11 on each of the HADS-D and HADS-A [@bb0130]. We also adjusted for the change from baseline to the end of study visit in the ESS score to evaluate whether any CPAP treatment effects on depression and anxiety were independent of changes in sleepiness. Based on the changes in absolute risk of depression and anxiety (HADS-D and HADS-A scores 8--21), we calculated the number needed to treat (NNT) at the end of follow-up [@bb0140]. The impact of CPAP adherence on depression and anxiety caseness was evaluated in patients randomised to CPAP treatment using logistic regression adjusted for other confounders. CPAP adherent was defined as having used ≥ 4 h (on average per night over a 48 months period), which is a widely used cut-off in prior studies [@bb0040], [@bb0145]. Heterogeneity in the CPAP treatment effect on HADS-D and HADS-A was assessed across subgroups defined by age (≤ 65 vs \> 65 years) sex, ethnicity (Asian vs non-Asian), body mass index (BMI, \< 30 vs ≥ 30 kg/m^2^), baseline depression and anxiety symptoms (HADS-D and HADS-A scores \< 8 vs ≥ 8, respectively), OSA severity (Apnoea Hypopnea Index \[AHI\] \< 30 vs ≥ 30 events/h), daytime sleepiness (ESS scores ≤ 10 vs \> 10), history of coronary artery disease and cerebrovascular disease, through the addition of interaction terms to the logistic regression models. Longitudinal changes in mean HADS-D and HADS-A scores by treatment group were visually examined with trajectory plots, and the between-group differences assessed using a linear mixed effects model with group, time, and a group\*time interaction as fixed effects; the overall difference between groups in trajectories were assessed using the p-value for the group\*time interaction term. We also assessed temporal changes in the individual components of the HADS using similar linear mixed effects models. All tests were two-sided and statistical significance set at P \< 0·05. Results are presented with 95% confidence intervals (CI). Analyses were undertaken using SAS 9·0 (SAS Institute, Cary, NC, USA) and STATA 14·2 (StataCorp, College Station, TX, USA).

2.5. Systematic review {#s0035}
----------------------

The systematic review protocol was registered in PROSPERO (CRD42017078483) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [@bb0150]. Inclusion criteria were all randomised controlled trials with consecutive patient recruitment, including parallel and crossover designs, comparing CPAP to non-active controls (oral placebo, standard care, or sham-CPAP) for mood improvement in adults (≥ 18 years and CPAP-naïve) with clinically diagnosed OSA. The included trials required depressive and/or anxiety symptoms measurement using validated questionnaires/clinical interviews that included the Beck\'s Depression Inventory (BDI) [@bb0155], HADS [@bb0135], Montgomery-Åsberg Depression rating scale (MADRS) [@bb0160], Profile of Mood States depression subscale [@bb0165], or the Geriatric Depression Scale (GDS) [@bb0170]. Trials of patients with co-morbid bipolar disorder, schizophrenia, or another psychiatric diagnosis, were excluded because of the potential to compromise CPAP adherence, follow-up, and outcome assessments. Five databases were searched: MEDLINE, EMBASE, PsychINFO, CINAHL and CENTRAL (from inception to August 2018), using adapted versions of the outlined Medline search strategy without language restrictions ([Table 1](#t0005){ref-type="table"}, appendix). Further literature was reviewed from reference lists of key clinical trials and previous systematic reviews [@bb0030], [@bb0040], [@bb0045].Table 1Hospital Anxiety and Depression Scale (HADS) scores among patients with obstructive sleep apnoea and cardiovascular disease at the end of follow-up in the SAVE trial (n = 2410).Table 1CPAP\
(Total n = 1220)\
n (%)Usual care\
(Total n = 1190)\
n (%)Crude OR (95%CI)P-valueAdjusted OR[⁎](#tf0005){ref-type="table-fn"}\
(95% CI)P-valueHADS-D[†](#tf0010){ref-type="table-fn"}Any depressive symptoms (score 8--21)[‡](#tf0015){ref-type="table-fn"}221 (18·1)295 (24·8)0·67 (0·55--0·82)\< 0·00010·80 (0·65--0·98)0·031Depression (score 11--21)92 (7·5)115 (9·7)0·76 (0·57--1·02)0·0640·96 (0·71--1·30)0·80HADS-A[†](#tf0010){ref-type="table-fn"}Any anxiety symptoms (score 8--21)[§](#tf0020){ref-type="table-fn"}176 (14·4)202 (17·0)0·83 (0·66--1·03)0·0860·98 (0·78--1·24)0·89Anxiety (score 11--21)62 (5·1)61 (5·1)0·99 (0·69--1·42)0·961·24 (0·84--1·81)0·28[^1][^2][^3][^4][^5]

Article screening and data extraction were conducted independently by three authors (DZ, YX, SY) and discrepancies resolved in discussion. Trials were included in the meta-analysis if they reported mean and SD in depression and/or anxiety scores post-intervention in treatment and control groups. We pooled standardised mean differences (and 95% CI) using random effects model of Dersimonian and Laird. Study weights were generated using the inverse of the variance. Between-study heterogeneity was assessed using the I^2^ statistic in combination together with visual inspection of the forest plots. Subgroup analyses by type of comparator (standard care, oral placebo, and sham-CPAP) also were conducted. The risk of bias assessment was performed by two independent reviewers (YX and XW) using the Cochrane risk of bias assessment tool [@bb0175]. Funnel plots and Egger\'s test were used to assess for publication bias. As the SAVE trial had the largest sample size compared to all other studies, we performed meta-analyses excluding the SAVE study as sensitivity analyses. Meta-analyses and publication bias assessment were conducted using STATA 14·2 (StataCorp, College Station, TX, USA) and risk of bias tables were produced using Revman 5·3 (Revman, The Cochrane Collaboration Oxford, UK).

3. Results {#s0040}
==========

3.1. SAVE study {#s0045}
---------------

There were 2687 patients of the SAVE study who underwent randomisation (1346 to CPAP intervention and 1341 to usual care alone) and were followed for major CV outcomes for a mean of 3·7 (SD 1.6) years ([Fig. 1](#f0005){ref-type="fig"}). For the present analyses, we included 2410 participants who had end of study mood assessment data. Patients included in this study tended to be younger, with higher use of antihypertensive and antithrombotic medication at baseline, and had greater adherence to sham-CPAP during the screening phase of the trial, compared to the 277 patients without end of study mood data who were excluded from these analyses (Table 2, Appendix). However, the included patients were well balanced for characteristics between CPAP treatment and usual care groups (Table 3, Appendix). At the end of study follow-up, 221/1220 (18·1%) individuals in the CPAP group and 295/1190 (24·8%) in the standard care group had 'depression caseness' (HADS-D score ≥ 8) ([Table 1](#t0005){ref-type="table"}). The unadjusted OR was 0·67 (95% CI 0·55--0·82; P \< 0·0001), and the effect remained significant after adjustment for the change in ESS scores during follow-up (adjusted OR 0·80, 95% CI 0·65--0·98; P = 0·031). In longitudinal analysis of the HADS-D, there was an overall reduction in depressive symptoms (p \< 0·0001 for group\*time interaction) and significantly fewer subjects with 'depression caseness' at most follow-up visits in the CPAP group; the treatment effect being apparent at 6 months post-randomisation ([Fig. 1](#f0005){ref-type="fig"}, Table 4, Appendix). Depression caseness with a higher cut-point score ≥ 11 on the HADS-D was also lower in the CPAP compared to usual care group, but the effect was not significant due to small patient numbers ([Table 1](#t0005){ref-type="table"}). The number needed to treat (NNT) in order to prevent one case of depression was 15 (95% CI 10--31). There appeared to be no significant effect of CPAP adherence on depression and anxiety (Table 5, appendix). Subgroup analyses showed that patients with pre-existing depression symptoms had significantly reduced depression symptoms with CPAP treatment (Table 6, appendix). Analyses of each of the questions on the HADS-D showed a consistent effect of CPAP treatment across individual symptom components ([Fig. 2](#f0010){ref-type="fig"}, appendix). Anxiety caseness (defined by HADS-A scores ≥ 8) was non-significantly lower in the CPAP group (176/1220, 14·4%) compared to usual care group (202/1190, 17·0%) ([Table 1](#t0005){ref-type="table"}). A trajectory plot of anxiety symptoms (HADS-A score) showed small reductions in anxiety in both usual care and CPAP groups over time, being slightly greater in those assigned to CPAP ([Fig. 3](#f0015){ref-type="fig"}, Table 4, appendix). Analyses of the individual questions on the HADS showed that CPAP treatment reduced four individual components of the HADS-A (Fig. 4, appendix).Fig. 1Consort flow diagramCPAP denotes continuous positive airways pressure; OSA, obstructive sleep apnoea.Fig. 1Fig. 2Meta-analysis of the effect of CPAP for depression symptomsPooled standardised mean difference (SMD) was calculated using a random effects model. Boxes are SMD and lines are 95% confidence interval (CI). The vertical solid line represents no difference between CPAP and control. Values to the left of the solid line favour CPAP benefit. Pooled SMDs and 95%CI are represented by the diamond shapes.Fig. 2Fig. 3Meta-analysis of the effect of CPAP for anxiety symptomsPooled standardised mean difference (SMD) was calculated using a random effects model. Boxes are SMD and lines are 95% confidence interval (CI). The vertical solid line represents no difference between CPAP and control. Values to the left of the solid line favour CPAP benefit. Pooled SMD and 95%CI are represented by diamond shapes.Fig. 3

3.2. Systematic review and meta-analysis {#s0050}
----------------------------------------

Our systematic search identified 1624 articles, with full text review identifying 20 eligible studies (4255 participants) that evaluated changes in depression and/or anxiety symptoms in response to CPAP in OSA patients (Table 7, Fig. 5, Appendix). All 20 included trials reported on depression symptoms for CPAP, although only 17 (4057 participants) had the necessary numerical data for inclusion in a meta-analysis. The overall standardised mean difference for depression symptoms for CPAP versus control was − 0·18 (95%CI -0·24 to − 0·12) ([Fig. 2](#f0010){ref-type="fig"}). We identified 13 trials with outcomes related to anxiety symptoms for quantitative synthesis: the overall standardised mean difference for anxiety symptoms for CPAP versus control was − 0·07 (− 0·17 to 0·04) ([Fig. 3](#f0015){ref-type="fig"}). In subgroup meta-analysis stratified by the type of control group used, CPAP was superior to both standard care and oral placebo for depression symptoms, while anxiety symptoms were alleviated with CPAP only when compared to standard care. By contrast, there was no effect of CPAP treatment when compared to sham-CPAP treatment for either depression ([Fig. 2](#f0010){ref-type="fig"}) or anxiety ([Fig. 3](#f0015){ref-type="fig"}). Sensitivity analyses excluding the SAVE trial from meta-analyses showed similar results to the main analyses (Figs. 6--7, Appendix). The included trials were mostly of high quality (Fig. 8, Appendix) and there was low between-study heterogeneity (I^2^ values 0% and 23·6% for depression and anxiety studies respectively). There was no evidence of publication bias (Figs. 9--10 Appendix).

4. Discussion {#s0055}
=============

Mood disorders are common in patients at high risk of CV disease, and depression in particular is associated with premature mortality and recurrent CV events [@bb0180], [@bb0185]. In the SAVE study of 2687 patients with established CV disease and OSA who were followed over several years, CPAP was found to significantly reduce the rates of clinically significant 'caseness' of depression but not of anxiety. The effect of CPAP occurred within several months of commencing the treatment, independently of improvements in daytime sleepiness, and was greater in those with pre-existing depression. Taken together with a systematic review of 20 randomised controlled studies, these results support a beneficial effect of CPAP treatment for the alleviation of depression symptoms.

The relationship between sleep disturbance and abnormal mood is strong and bidirectional [@bb0190], [@bb0195]. In OSA patients, there are a range of relevant pathophysiological mechanisms operating that include apnoea-induced sleep fragmentation, hypoxia, and daytime sleepiness, cerebral grey matter structural changes, and metabolic abnormalities, which may be reversed by CPAP treatment [@bb0015], [@bb0200], [@bb0205], [@bb0210], [@bb0215], [@bb0220]. This study defines a clear effect of CPAP treatment on depressive symptoms which acts independently of improvements in daytime sleepiness. Although analysis of depression symptoms as a continuous variable did not show any difference between CPAP and usual care groups at 72 months timepoint, this is likely due to small numbers of patients at this stage of the study. A detailed analysis of the individual components of the HADS-D also showed a consistent effect of CPAP treatment across all of the questions including those related to sleepiness, such as "feeling slowed down" and anhedonia-oriented symptoms. These effects remained after adjustment for the change in sleepiness (ESS) during follow-up. Sub-group analysis of the SAVE study also showed a greater effect of CPAP in those with prior depression, which is consistent with a prior systematic review [@bb0040]. As the NNT (i.e. 15) for CPAP to prevent depression is comparable to remission rates achieved for some established antidepressant drugs [@bb0225], our findings provide further support for the broader beneficial effects of CPAP in those with OSA, and especially those at high CV risk, where there is the potential for enhanced mood to improve long-term CV outcomes [@bb0145], [@bb0225].

Although improvements were observed in four (out of seven) individual components of the HADS-A subscale, the rate of anxiety caseness was not significantly lower among the CPAP treated patients at the end of study. The lack of significant difference in rates of anxiety caseness between the groups may be largely due to parallel improvements in symptoms in the usual care group, although an anxiety inducing effect of CPAP from, for example, from the mask application, may also be relevant. Another issue is a steady reduction in anxiety symptoms in both groups which might arise as a result of repeated testing and regular interactions with health care workers (i.e. the Hawthorne effect) [@bb0120].

Our systematic review and meta-analysis confirmed the efficacy of CPAP in reducing depression but not anxiety symptoms. The overall neutral effect of CPAP treatment on anxiety symptoms may be due to a slight positive, albeit non-significant effect of sham-CPAP as compared to therapeutic CPAP in several included trials. The reduction in depression symptoms from CPAP occurred when compared to placebo pill or usual care, but not when compared with sham-CPAP. Sham-CPAP is designed to provide flow of air via a face mask at very low sub-therapeutic pressure; the mask and pump being identical in appearance to true CPAP, with the exception that the mask has a larger hole for venting air. The use of sham-CPAP as a true control in CPAP studies has been controversial, and earlier studies have found small improvements in sleep and respiratory parameters as a result of its use [@bb0230], [@bb0235], [@bb0240]. A study on sham-CPAP reported small changes in OSA patients toward worse quality sleep but a reduced severity of sleep disordered breathing (complete airway obstruction \[apneas\] tending to be replaced by partial obstruction events \[hypopneas\]) and a reduced overnight burden of hypoxia [@bb0240]. It is possible, therefore, that sham-CPAP may obscure some of the effects of CPAP on depression and anxiety symptoms [@bb0245], and further research is warranted to better define the effects of sham-CPAP on mood.

Key strengths of these analyses are that they were derived from the SAVE study, the largest randomised evaluation of the effects of CPAP for OSA in CV patients who were well characterised and followed up in a range of clinical settings, thus providing high validity and generalisability of the findings. Moreover, the SAVE study allowed an evaluation of treatment effects on depression and anxiety symptoms over a substantially longer time period than has previously been undertaken, and incorporation of these data into a systematic review of other trials provided reliability and consistency of findings. However, there are some limitations, particularly in the use of screening tools to assess mood outcomes as opposed to gold standard, semi-structured, psychiatric interviews. Even so, self-reported depression and anxiety scores are more relevant to routine clinical practice (easy to administer, low cost), and are highly correlated with clinical diagnoses of depression and anxiety [@bb0130], [@bb0250]. Although we used recommended cut-point scores of eight on both HADS-A and HADS-D subscales to provide an optimum balance of sensitivity and specificity for abnormal mood in studies [@bb0130], screening instruments are prone to misdiagnosis and clinical uncertainty regarding appropriate clinical pathways for care. Another limitation is that we lacked information on psychotropic medicines which may confound the results, although patients with major mental illness would likely have avoided participating in such studies. Moreover, as we only included patients with coexisting moderate--severe OSA and CV disease, our results may not be generalisable to patients with mild OSA or broader OSA population without CV disease. For the systematic review, there are clear limitations to the various component trials, including the lack of blinding of patients or their outcome assessors, short duration of follow-up, and variable adherence to CPAP. Finally, a few studies were excluded due to a lack of numerical data for statistical synthesis [@bb0090], [@bb0110], [@bb0255].

5. Conclusion {#s0060}
=============

In summary, our detailed analysis of the SAVE study has shown that CPAP for moderate--severe OSA in patients with CV disease has broader benefits in terms of preventing depression caseness, independent of improved sleepiness. Our additional systematic review provides further support of the treatment effect of CPAP for depression, but not for anxiety symptoms.
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[^1]: CI denotes confidence interval; CPAP, continuous positive airways pressure; HADS-D Hospital Anxiety and Depression Scale - Depression subscale score; HADS-A Hospital Anxiety and Depression Scale -- Anxiety subscale score; SD, standard deviation.

[^2]: Logistic regression adjusted for change in Epworth Sleepiness Scale score from baseline to end of study.

[^3]: HADS-A and HADS-D scores range from 0 to 21, with higher scores indicating more severe symptoms.

[^4]: Number needed to treat to prevent depression caseness (HADS-D score 8--21) for 3·7 years is 15 (95% confidence interval 10 to 31).

[^5]: Number needed to treat to prevent anxiety caseness (HADS-A score 8--21) for 3·7 years is 39 (95% confidence interval 18 to − 281).
